About Tranquis Therapeutics

Tranquis Therapeutics is developing small molecule drugs that reprogram dysfunctional immune cells to restore mitochondrial and lysosomal function, targeting neurodegenerative and aging-related diseases. Their therapies aim to improve cellular homeostasis, potentially transforming the treatment landscape for a range of central nervous system and non-central nervous system conditions.

```xml <problem> Many neurodegenerative and aging-related diseases are associated with dysfunctional immune cells that have impaired mitochondrial and lysosomal function. This cellular dysfunction contributes to disease progression and limits the effectiveness of existing treatments. </problem> <solution> Tranquis Therapeutics is developing small molecule drugs designed to reprogram dysfunctional immune cells and restore normal mitochondrial and lysosomal function. These therapies aim to re-establish cellular homeostasis, addressing the underlying mechanisms of neurodegenerative and aging-related diseases. By targeting the energy metabolism of dysfunctional immune cells, Tranquis Therapeutics seeks to modify disease progression and improve patient outcomes across a range of central nervous system (CNS) and non-CNS indications. Their therapeutic candidates act as master regulators of mitochondrial and lysosomal function, offering a novel approach to managing these complex conditions. </solution> <features> - Small molecule drugs designed to reprogram dysfunctional immune cells. - Therapies target and restore normal mitochondrial function. - Therapies target and restore normal lysosomal function. - Aims to re-establish cellular homeostasis. - Potential application across a range of CNS and non-CNS indications. </features> <target_audience> The primary target audience includes patients suffering from neurodegenerative and aging-related diseases, as well as healthcare providers seeking innovative treatments for these conditions. </target_audience> ```

What does Tranquis Therapeutics do?

Where is Tranquis Therapeutics located?

Tranquis Therapeutics is based in San Mateo, Philippines.

When was Tranquis Therapeutics founded?

Tranquis Therapeutics was founded in 2016.

How much funding has Tranquis Therapeutics raised?

Tranquis Therapeutics has raised 32000000.

Location

San Mateo, Philippines

Founded

2016

Funding

32000000

Employees

8 employees

Major Investors

SR One, Remiges Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Tranquis Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

tranquis.com 1K+

Crunchbase

Founded 2016 – San Mateo, Philippines

Funding

Estimated Funding

$20M+

Major Investors

SR One, Remiges Ventures

Team (5+)

No team information available.

Company Description

Problem

Many neurodegenerative and aging-related diseases are associated with dysfunctional immune cells that have impaired mitochondrial and lysosomal function. This cellular dysfunction contributes to disease progression and limits the effectiveness of existing treatments.

Solution

Tranquis Therapeutics is developing small molecule drugs designed to reprogram dysfunctional immune cells and restore normal mitochondrial and lysosomal function. These therapies aim to re-establish cellular homeostasis, addressing the underlying mechanisms of neurodegenerative and aging-related diseases. By targeting the energy metabolism of dysfunctional immune cells, Tranquis Therapeutics seeks to modify disease progression and improve patient outcomes across a range of central nervous system (CNS) and non-CNS indications. Their therapeutic candidates act as master regulators of mitochondrial and lysosomal function, offering a novel approach to managing these complex conditions.

Features

Small molecule drugs designed to reprogram dysfunctional immune cells.

Therapies target and restore normal mitochondrial function.

Therapies target and restore normal lysosomal function.

Aims to re-establish cellular homeostasis.

Potential application across a range of CNS and non-CNS indications.

Target Audience

The primary target audience includes patients suffering from neurodegenerative and aging-related diseases, as well as healthcare providers seeking innovative treatments for these conditions.